- Home
- SONN
as 12-27-2024 4:00pm EST
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.5M | IPO Year: | N/A |
| Target Price: | $38.00 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.41 - $18.72 | Next Earning Date: | 12-17-2024 |
| Revenue: | $18,626 | Revenue Growth: | -87.40% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Sonnet BioTherapeutics Holdings Inc. News
SONN Breaking Stock News: Dive into SONN Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
GlobeNewswire
11 days ago
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
19 days ago
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
19 days ago
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
GlobeNewswire
24 days ago
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action
GlobeNewswire
2 months ago
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
GlobeNewswire
2 months ago
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
2 months ago
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Compare SONN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SONN Sonnet BioTherapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.